Chemoradiotherapy for anal cancer: are we as good as we think?
Radiochemotherapie für das Analkarzinom: Sind wir so gut, wie wir denken?
Anus Neoplasms
/ mortality
Carcinoma, Squamous Cell
/ mortality
Chemoradiotherapy
/ methods
Cohort Studies
Combined Modality Therapy
Disease-Free Survival
Fluorouracil
/ administration & dosage
Mitomycin
/ administration & dosage
Neoplasm Staging
Progression-Free Survival
Radiotherapy Dosage
Randomized Controlled Trials as Topic
Retrospective Studies
Chemotherapy
Lymph nodes
Outcome
Prognosis
Stage
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
03
10
2018
accepted:
14
02
2019
pubmed:
3
4
2019
medline:
22
1
2020
entrez:
3
4
2019
Statut:
ppublish
Résumé
Definitive chemoradiotherapy (CRT) is the standard treatment for anal squamous cell carcinoma (ASCC). Data regarding treatment outcome according to TNM classification is scarce. Here, we review data of randomized trials and retrospective cohorts suggesting a poor 3‑year disease-free survival (DFS; or progression-free survival, PFS) of approximately 60%, or even lower, in patients with locally advanced T3-4 and/or N+ disease, while patients with T1-2N0 ASCC have 3‑year DFS/PFS rates exceeding 80%. These results are in line with our data in a cohort of 210 patients with ASCC treated with definitive 5‑fluorouracil/mitomycin C‑based CRT to a total dose of 50.4 Gy plus a boost of 3.6-10.8 Gy. The implications of these findings and the current trials testing radiotherapy dose escalation/de-escalation strategies are reported. Finally, we will discuss the strong rationale for testing immune checkpoint blockade (ICB) with CRT in clinical trials to improve results, especially in patients with advanced ASCC.
Identifiants
pubmed: 30937508
doi: 10.1007/s00066-019-01444-7
pii: 10.1007/s00066-019-01444-7
doi:
Substances chimiques
Mitomycin
50SG953SK6
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
369-373Références
Br J Surg. 2002 Nov;89(11):1425-9
pubmed: 12390386
JAMA. 2008 Apr 23;299(16):1914-21
pubmed: 18430910
Br J Cancer. 2010 Mar 30;102(7):1123-8
pubmed: 20354531
Cancer. 2010 Sep 1;116(17):4007-13
pubmed: 20564111
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):552-8
pubmed: 22019078
J Clin Oncol. 2012 Jun 1;30(16):1941-8
pubmed: 22529257
Cancer. 2013 Feb 15;119(4):748-55
pubmed: 23011911
Radiol Oncol. 2012 Jun;46(2):145-52
pubmed: 23077451
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Lancet Oncol. 2013 May;14(6):516-24
pubmed: 23578724
Histol Histopathol. 2014 Apr;29(4):513-21
pubmed: 24122611
Cancer Epidemiol. 2013 Dec;37(6):807-12
pubmed: 24139594
PLoS One. 2014 Mar 18;9(3):e92071
pubmed: 24642661
APMIS. 2015 Jan;123(1):53-9
pubmed: 25244542
Radiother Oncol. 2014 Dec;113(3):352-8
pubmed: 25499203
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Cancer Epidemiol Biomarkers Prev. 2015 Oct;24(10):1548-56
pubmed: 26224796
Brachytherapy. 2016 Nov - Dec;15(6):865-872
pubmed: 27720203
Am J Clin Oncol. 2018 Jul;41(7):638-642
pubmed: 27849650
J Clin Oncol. 2017 Mar;35(7):727-733
pubmed: 27937092
Clin Oncol (R Coll Radiol). 2017 Apr;29(4):248-255
pubmed: 28049602
J Clin Oncol. 2017 Mar;35(7):718-726
pubmed: 28068178
Lancet Oncol. 2017 Apr;18(4):446-453
pubmed: 28223062
Oncoimmunology. 2017 Feb 6;6(3):e1288331
pubmed: 28405521
Ann Oncol. 2017 May 1;28(5):1036-1041
pubmed: 28453692
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Cancer Manag Res. 2017 Dec 18;10:1-11
pubmed: 29296096
Cancer Treat Rev. 2018 Apr;65:11-21
pubmed: 29494827
Acta Oncol. 2018 Nov;57(11):1427-1437
pubmed: 30264638
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Strahlenther Onkol. 2018 Nov 2;:null
pubmed: 30390114
Cancer. 1983 May 15;51(10):1826-9
pubmed: 6831348
Lancet. 1996 Oct 19;348(9034):1049-54
pubmed: 8874455